Sanofi (SNY)
(Delayed Data from NSDQ)
$46.61 USD
-1.08 (-2.26%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $46.51 -0.10 (-0.21%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Income Statements
Fiscal Year end for Sanofi falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 50,266 | 47,822 | 46,348 | 42,687 | 42,147 |
Cost Of Goods | 15,408 | 14,429 | 14,499 | 13,887 | 13,413 |
Gross Profit | 34,859 | 33,393 | 31,849 | 28,800 | 28,734 |
Selling & Adminstrative & Depr. & Amort Expenses | 25,265 | 22,672 | 22,003 | 12,411 | 21,464 |
Income After Depreciation & Amortization | 9,594 | 10,720 | 9,846 | 16,389 | 7,270 |
Non-Operating Income | -431 | 724 | -185 | -175 | -3,612 |
Interest Expense | 1,421 | 464 | 435 | 446 | 497 |
Pretax Income | 7,742 | 10,981 | 9,226 | 15,768 | 3,161 |
Income Taxes | 1,734 | 2,114 | 1,843 | 2,071 | 156 |
Minority Interest | 39 | 119 | 66 | 41 | 35 |
Investment Gains/Losses | -124 | 72 | 46 | 410 | 286 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5,883 | 8,939 | 7,429 | 14,107 | 3,291 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 5,844 | 8,820 | 7,362 | 14,066 | 3,256 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 14,780 | 14,324 | 13,810 | 20,597 | 15,616 |
Depreciation & Amortization (Cash Flow) | 5,186 | 3,603 | 3,965 | 4,208 | 8,346 |
Income After Depreciation & Amortization | 9,594 | 10,720 | 9,846 | 16,389 | 7,270 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2,503.40 | 2,503.80 | 2,505.00 | 2,507.20 | 2,505.36 |
Diluted EPS Before Non-Recurring Items | 4.39 | 4.35 | 3.88 | 3.35 | 3.32 |
Diluted Net EPS (GAAP) | 2.33 | 3.51 | 2.93 | 5.58 | 1.25 |
Fiscal Year end for Sanofi falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 13,137.84 | 13,820.50 | 11,647.65 | 11,660.34 |
Cost Of Goods | NA | 4,358.65 | 4,180.54 | 3,563.43 | 3,305.00 |
Gross Profit | NA | 8,779.19 | 9,639.96 | 8,084.23 | 8,355.35 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7,403.18 | 6,137.49 | 6,045.18 | 5,679.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1,376.01 | 3,502.47 | 2,039.05 | 2,676.00 |
Non-Operating Income | NA | -843.70 | 148.02 | 124.31 | 140.62 |
Interest Expense | NA | 674.36 | 346.11 | 220.26 | 180.33 |
Pretax Income | NA | -142.05 | 3,304.38 | 1,943.09 | 2,636.27 |
Income Taxes | NA | 332.89 | 612.77 | 295.50 | 492.69 |
Minority Interest | NA | -3.30 | 14.15 | 13.08 | 15.03 |
Investment Gains/Losses | NA | -138.31 | 70.75 | -69.79 | 12.88 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -613.25 | 2,762.36 | 1,577.81 | 2,156.46 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -609.95 | 2,748.21 | 1,564.72 | 2,141.43 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 2,507.20 | 2,475.49 | 2,501.20 | 2,498.60 |
Diluted EPS Before Non-Recurring Items | NA | 0.89 | 1.39 | 0.95 | 1.16 |
Diluted Net EPS (GAAP) | NA | -0.25 | 1.10 | 0.63 | 0.86 |